A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA studyShun Lü, Weiguo Su, Yuping Sun et al.|Lung Cancer|2020Cited by 21